Recent Updates
Recently added Catalysts

BioXcel Therapeutics, Inc.

BTAIQFDA catalysts, PDUFA dates & pipeline intelligence
$0.01
▲ 0 · +29.15%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BTAIQ financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
134.81 K
Value Traded
1.33 K
Short % Float
-
Days to Cover
3.3
+48.75%Week

Cash Data

Unlock BTAIQ cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
372.54 K
EPS (TTM)
-
P/E Ratio
-
Ent. Value
196.43 M
Total Shares
31.31 M
Float Shares
-
Insiders
-
Institutions
-

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every BTAIQ catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BTAIQ Catalyst Timeline

Dated clinical, regulatory and corporate events for BioXcel Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for BioXcel Therapeutics, Inc.

3Total events
3Upcoming
3Tier-1 (high impact)
2026 to 2026Coverage

Upcoming catalysts 2

T1PDUFA Date
Subscribe to view catalyst details
IGALMI
T1PDUFA Date
Subscribe to view catalyst details
BXCL501
Unlock the full BTAIQ catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BTAIQ actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all BTAIQ historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 62%
Micro Cap
(rank 426 of 687)
Percentile Rank
Showing 6 of 12 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
BXCL501 Small MoleculesNCT05025605SchizophreniaPhase 1 RECRUITING 140Dec 31, 2027
Talabostat Small MoleculesCompletedNCT03910660Prostate CancerPhase 1/2 COMPLETED 97Aug 31, 2025
BXCL501 Film Small MoleculesCompletedNCT07116694Bipolar I DisorderPhase 2 COMPLETED 33Oct 7, 2025
BXCL501 Small MoleculesCompletedNCT05658510Agitation,PsychomotorPhase 3 COMPLETED 452Aug 15, 2025
BXCL501 Small MoleculesCompletedNCT05271552AgitationPhase 3 COMPLETED 151Apr 21, 2023
film containing Dexmedetomidine Small MoleculesCompletedNCT04251910Agitation,PsychomotorPhase 1/2 COMPLETED 100Jan 24, 2022
Unlock the BTAIQ pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BTAIQ program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every BTAIQ trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BTAIQ insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full BTAIQ insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in BTAIQ

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in BTAIQ for Q2 2026.
Unlock every fund holding BTAIQ
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BTAIQ
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see BTAIQ ownership
Insider and institutional ownership, quarter by quarter.

BTAIQ Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
1.4M
Shares Sold Short
-13.5% vs prior count
3.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
432.3K
Avg Daily Volume
the average used for days to cover
Unlock BTAIQ short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock BTAIQ option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BTAIQ option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BTAIQ options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BTAIQ ranks across every disease it competes in

Competitive Position is a premium feature
See how BTAIQ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BTAIQ News

About BioXcel Therapeutics, Inc.

BIOPHARMAWATCH ELITE
Trade the next BTAIQ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime